ISA Pharmaceuticals

Executive Summary

ISA Pharmaceuticals is a Dutch biotechnology company leveraging its proprietary synthetic long peptide (SLP) platform to develop immunotherapies and vaccines for cancer and infectious diseases. Founded in 2004 and headquartered in Leiden, the company focuses on eliciting robust T-cell responses by designing SLPs that target specific antigens. While the company has not yet disclosed detailed pipeline data or reached late-stage clinical trials, its SLP technology has the potential to address significant unmet medical needs in oncology and infectious diseases, particularly in the context of personalized medicine. The company operates in a competitive landscape but may benefit from partnerships or collaborations to advance its candidates. Given the early-stage nature and limited public information, the conviction score is moderate, reflecting both the promise of the technology and the inherent risks of early-stage biotech.

Upcoming Catalysts (preview)

• Q3 2026Initiation or update of Phase 1/2 clinical trial for lead SLP vaccine candidate45% success
• Q4 2026Strategic partnership or licensing deal for SLP platform in oncology or infectious diseases30% success
• Q1 2027Publication of preclinical data or proof-of-concept results in peer-reviewed journal70% success